A carregar...
Enhanced patient support services improve patient persistence with multiple sclerosis treatment
BACKGROUND: Subcutaneous interferon beta-1a (sc IFN β-1a) therapy (44 µg or 22 µg, three times weekly) improves relapse rates and disability progression in patients with relapsing multiple sclerosis (MS). While early treatment with disease-modifying drugs may maximize therapeutic benefit, patients w...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4062553/ https://ncbi.nlm.nih.gov/pubmed/24966668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S59496 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|